BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms

Blood

Volumn 110, Issue 6, 2007, Pages 2067-2074

  Parekh, Samir ^a   Polo, Jose M ^a   Shaknovich, Rita ^a   Juszczynski, Przemyslaw ^b   Lev, Paola ^a   Ranuncolo, Stella M ^a   Yin, Gnan ^a   Klein, Ulf ^c   Cattoretti, Giorgio ^d   Dalla Favera, Riccardo ^c   Shipp, Margaret A ^b   Melnick, Ari ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; NUCLEAR RECEPTOR COREPRESSOR; PROTEIN BCL 6; PROTEIN MTS3; PROTEIN PRDM1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE LOCUS; GERMINAL CENTER; HUMAN; HUMAN CELL; INTRON; LARGE CELL LYMPHOMA; LYMPHOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

EID: 34548256410     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-069575     Document Type: Article

References (33)

1. Ye BH, Lista F, Lo Coco F, et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 1993;262:747-750.
2. Wang X, Li Z, Naganuma A, Ye BH. Negative autoregulation of BCL-6 is bypassed by genetic alterations in diffuse large B cell lymphomas. Proc Natl Acad Sci U S A. 2002;99:15018-15023.
3. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997;276:589-592.
4. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16:161-170.
5. Ranuncolo SM, Polo JM, Dierov J, et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol. 2007;8:705-714.
6. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432:635-639.
7. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol. 2005;6:1054-1060.
8. Polo J, Juszczynski P, Monti S, et al. A transcriptional signature with differential expression of BCL6 target genes identifies BCL6-dependent diffuse large B-cell lymphomas. Proc Natl Acad Sci U S A. 2007;104:3207-3212.
9. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13:199-212.
10. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J Immunol. 2004;173:1158-1165.
11. Vasanwala FH, Kusam S, Toney LM, Dent AL. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol. 2002;169:1922-1929.
12. Lin KI, Tunyaplin C, Calame K. Transcriptional regulatory cascades controlling plasma cell differentiation. Immunol Rev. 2003;194:19-28.
13. Huynh KD, Bardwell VJ. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene. 1998;17:2473-2484.
14. Huynh KD, Fischle W, Verdin E, Bardwell VJ. BCoR, a novel corepressor involved in BCL-6 repression. Genes Dev. 2000;14:1810-1823.
15. Ahmad KF, Melnick A, Lax S, et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell. 2003;12:1551-1564.
16. Polo JM, Dell'Oso T, Ranuncolo SM, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med. 2004;10:1329-1335.
17. Fujita N, Jaye DL, Geigerman C, et al. MTA3 and Mi-2/NuRD complex regulate cell fate during B-lymphocyte differentiation. Cell. 2004;119:75-86.
18. Klein U, Tu Y, Stolovitzky GA, et al. Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci U S A. 2003;100:2639-2644.
19. Juszczynski P, Kutok JL, Li C, Mitra J, Aguiar RC, Shipp MA. BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Mol Cell Biol. 2006;26:5348-5359.
20. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851-1861.
21. Shaknovich R, Celestine A, Yang L, Cattoretti G. Novel relational database for tissue microarray analysis. Arch Pathol Lab Med. 2003;127:492-494.
22. Cattoretti G, Chang CC, Cechova K, et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 1995;86:45-53.
23. Chang DH, Cattoretti G, Calame KL. The dynamic expression pattern of B lymphocyte induced maturation protein-1 (Blimp-1) during mouse embryonic development. Mech Dev. 2002;117:305-309.
24. Houldsworth J, Olshen AB, Cattoretti G, et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. Blood. 2004;103:1862-1868.
25. Cattoretti G, Buttner M, Shaknovich R, Kremmer E, Alobeid B, Niedobitek G. Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. Blood. 2006;107:3967-3975.
26. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
27. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
28. Cerchietti L, Polo J, DaSilva G, et al. BCL6, p53 and molecular targeted therapy in B-cell lymphomas. Blood. 2005;106: Abstract 1484.
29. Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? J Clin Oncol. 2005;23:3957-3970.
30. Chevallier N, Corcoran CM, Lennon C, et al. ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood. 2004;103:1454-1463.
31. Miles RR, Crockett DK, Lim MS, Elenitoba-Johnson KS. Analysis of BCL6-interacting proteins by tandem mass spectrometry. Mol Cell Proteomics. 2005;4:1898-1909.
32. Melnick A, Licht JD. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999;93:3167-3215.
33. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759-767.